Infectious Disease Therapeutics Market to Grow with a CAGR of 7.00% through 2029
Persistent disease burden, the rise of antimicrobial
resistance, and advancements in biotechnology are factors driving the Global
Infectious Disease Therapeutics market in the forecast period 2025-2029
According
to TechSci Research report, “Infectious Disease Therapeutics Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2029”, the Global Infectious Disease Therapeutics Market stood at USD 67.04
billion in 2023 and is anticipated to grow with a CAGR of 7.00% in the forecast
period, 2025-2029. Government and private sector investments have spurred the
advancements in infectious disease therapeutics. Both governmental bodies and
private entities have intensified their funding for research and development in
this domain. Notably, agencies like the National Institutes of Health (NIH) in
the United States have allocated substantial resources to facilitate
groundbreaking research initiatives. Furthermore, pharmaceutical firms are
partnering with governments and organizations to hasten the development and
dissemination of therapeutic solutions. Additionally, the One Health strategy,
emphasizing the interconnection of human, animal, and environmental health, is
gaining traction. This comprehensive approach seeks to preempt zoonotic
diseases at their origin, enhancing overall health security.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Infectious Disease Therapeutics Market”
The
market is poised for a substantial influx of drug patent expirations throughout
the forecast period. These expirations result in the availability of generic
medications with identical compositions to branded counterparts but at
significantly reduced prices. Consequently, healthcare providers frequently
recommend these cost-effective generic drugs to patients. Furthermore, the
favorable reimbursement landscape, encompassing coverage for diagnosis and
treatment, is expected to propel market expansion. Key industry players are
actively innovating novel products for combating infectious diseases and
securing approvals for their commercialization. For instance, in December 2022,
Gilead Sciences received FDA approval for Sunlenca, a product targeting HIV-1 infection
in adults with multi-drug resistant HIV-1. However,
several factors may hinder growth in the coming years. One such factor is the
limited awareness of these diseases and the constrained adoption of treatments,
particularly prevalent in regions like Africa and Asia, which exhibit high
infectious disease prevalence rates but comparatively low treatment adoption
rates.
The Global Infectious Disease Therapeutics Market is
segmented into disease type, end use, regional distribution, and company.
Based
on disease type, the HIV segment dominated the market in terms of revenue in
2023. This was primarily due to the high prevalence of HIV/AIDS globally has
led to a sustained demand for effective treatments. Advancements in
antiretroviral therapy (ART) have significantly improved patient outcomes and
prolonged survival rates, driving market growth. The initiatives to increase
access to HIV treatment in developing countries, coupled with robust funding
from governments, international organizations, and philanthropic entities, have
further boosted market expansion. The ongoing research and development efforts
continue to yield innovative therapies, reinforcing the dominance of the HIV
segment in the infectious disease therapeutics market.
Based
on end use, the hospital segment dominated the market in 2023. This is due to several
compelling factors. Hospitals serve as primary centers for diagnosing,
treating, and managing infectious diseases, leading to a consistently high
demand for therapeutics. Hospitals often have access to advanced medical
technologies and specialized healthcare professionals, enabling them to provide
comprehensive and effective treatment regimens. The increasing prevalence of
infectious diseases globally has led to a surge in hospital admissions, driving
the demand for therapeutics within this segment. Combined, these factors
contribute to the hospital segment's prominent position in the infectious
disease therapeutics market. Meanwhile, the clinics segment is projected to
witness the highest Compound Annual Growth Rate (CAGR) throughout the forecast
period. This surge can be attributed to the escalating demand for outpatient
healthcare services, the availability of advanced diagnostic and therapeutic
facilities, and heightened public awareness of preventive measures. Clinics
offer a comprehensive array of services catering to infectious disease
patients, encompassing screening, testing, vaccination, counseling, and
treatment. They provide specialized care for intricate and uncommon infections
such as HIV/AIDS, tuberculosis, hepatitis, and COVID-19. Clinics actively
engage in clinical trials and research initiatives aimed at assessing the
safety and efficacy of novel drugs and vaccines for infectious diseases,
thereby fueling the expansion of this sector.
Major companies operating in Global Infectious Disease
Therapeutics Market are:
·
Novartis AG
·
Gilead Sciences Inc
·
GSK PLC
·
Janssen Pharmaceuticals Inc
·
F Hoffmann-La Roche AG
·
BioCryst Pharmaceuticals Inc
·
Merck & Co Inc
·
Boehringer Ingelheim International GmbH
Download Free Sample Report
Customers can also request for 10% free customization on
this report
“The
Global Infectious Disease Therapeutics Market is characterized by its dynamic
and evolving nature, influenced by innovative technologies, and changing
healthcare agendas. The market is poised to witness advancements in pandemic
preparedness strategies, the emergence of innovative solutions to combat
antimicrobial resistance (AMR), a heightened emphasis on vaccine development,
and the continued ascent of immunotherapies and gene-based therapies. These
trends underscore the ongoing evolution and adaptation within the market,
driven by a collective commitment to addressing the complexities of infectious
diseases and enhancing patient care on a global scale” said Mr. Karan Chechi,
Research Director, TechSci Research, a research-based management consulting
firm.
“Infectious
Disease Therapeutics Market By Disease
Type (HIV, Hepatitis, Influenza, TB, Malaria, HPV, Others), By End Use
(Hospitals, Clinics, Others), By Region, By Competition Forecast &
Opportunities, 2019-2029F”, has evaluated the future growth potential of Global
Infectious Disease Therapeutics Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Infectious Disease Therapeutics Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com